More than 80 international and regional healthcare experts have convened at the Pfizer MERA Maternal Immunization Summit: ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Recommendations supporting respiratory syncytial virus vaccines marketed by Pfizer (NYSE:PFE) and GSK (NYSE:GSK) made last ...

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

Of the RSV patients aged 60 or older, 23.0% were admitted to an ICU, 31.5% had acute organ failure, and 9.8% received IMV or ...

Far fewer babies went to the hospital struggling to breathe from RSV, a severe respiratory infection, after the debut of a new vaccine and treatment this season, according to an analysis published ...

GSK claims that Pfizer’s FDA-approved vaccine for respiratory syncytial virus infringes on four patents protecting its own approved vaccine, Arexvy. The patent suit comes with the RSV season ...

Recommendations supporting respiratory syncytial virus vaccines marketed by Pfizer (NYSE ... voted 14-0 to recommend a single shot of both RSV vaccines for adults aged 50-59 who are at increased ...